<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913276</url>
  </required_header>
  <id_info>
    <org_study_id>StV 15-2008</org_study_id>
    <nct_id>NCT00913276</nct_id>
  </id_info>
  <brief_title>Conditioning With Volatile Anesthetics in Liver Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Sao Paulo, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gap between the number of candidates for orthotopic liver transplantation and the
      availability of suitable liver grafts has led to a rise in deaths on most waiting lists.
      Strategies applied in many centers to minimize this deficit include living donation or split
      of a cadaveric organ for two recipients, domino transplantation, and the use of so-called
      expanded criteria donors. Alternatively, conditioning of an organ would also allow
      protec-tion of the liver upon ischemia-reperfusion injury, possibly decreasing postoperative
      liver function and im-proving clinical outcome. The technique of conditioning with the
      volatile anesthetic sevoflurane is an easily applicable procedure which could be performed in
      any center worldwide.

      Data and experience with sevoflurane attenuating ischemic-reperfusion injury in liver
      resection lead to the hypothesis of a beneficial effect of volatile anesthetics in liver
      transplantation. In this randomized controlled trial, patients will be randomly assigned to
      liver transplantation with propofol anesthesia (propofol group) or sevoflurane conditioning
      with the volatile anesthetic (sevoflurane group). Primary endpoint is postoperative peak of
      the transaminase (AST), secondary endpoints are complications, primary liver graft function,
      ICU and hospital stay. We hypothesis that patients with conditioning have an attenuated
      increase of transaminases as well as a better outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative paek of AST</measure>
    <time_frame>4 y</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>End-stage Liver Disease</condition>
  <arm_group>
    <arm_group_label>Sevoflurane anesthesia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol anesthesia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>Sevoflurane anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Older than 18 years

          -  Patients undergoing liver transplantation

          -  Total or partial cadaveric liver transplantation

          -  Living related liver transplantation

        Exclusion criteria:

          -  Patients unable to understand the German or Italian language

          -  Patients with known or suspected allergy to propofol, soja or egg

          -  Patients with norepinephrine infusion above 15 microg/min

          -  Intensive care patients with severe impairment of renal or pulmonary function (e.g.
             dialysis, hemofiltration, FiO2&gt;0.5)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Anaesthesiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

